BioSpace News Archive

Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms

PsyBio Therapeutics Corp. today announced that Evan Levine , Chief Executive Officer and Chairman, will participate in the Maxim Group Advances in Mental Health Virtual Conference and the Benzinga Virtual Global Healthcare Small Cap Conference in September 2021.

Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced they have entered into a research collaboration to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1)

Resin-based restorative materials are required in almost all modern dentistry procedures. Almost all resin-based restorative products in dentistry use the same basic monomer family and polymerization mechanism? Free radical addition polymerization of methacrylates and vinyl.

An increase in the prevalence of lifestyle diseases around the world and the rising geriatric population will serve as prominent reason for the growth of the human microbiome market during the forecast period of 2018-2026.

Endovascular processes particularly neuroendovascular interventions are becoming increasingly common in the treatment of cardiovascular disease and wide range of intracranial vascular lesions.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global lab scale bioreactors market is forecast to register a healthy compound annual growth rate between 2021 and 2031.

The Board of Directors of Nordic Nanovector ASA has on 20 September 2021 decided to grant 350,000 Performance Share Units to the Company’s new CEO and primary insider Mr. Erik Skullerud in accordance with the authorisation granted at the Annual General Meeting held on 28 April 2021.

GT Biopharma, Inc., a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer cell engager, TriKE platform, announced Dr. Jeffrey Miller’s mini-oral presentation at the European Society for Medical Oncology Congress 2021.

CASI Pharmaceuticals, Inc. announced that Dr. Alexander Zukiwski , Chief Medical Officer of CASI Pharmaceuticals, will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit